Clinical Trials
123
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (94 trials with phase data)⢠Click on a phase to view related trials
The Impact of Time Restricted Eating on Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 10
- Registration Number
- NCT06887543
- Locations
- đşđ¸
The Rockefeller University Hospital, New York, New York, United States
Thermogenic Silencer Regulatory Factors in Humans
- Conditions
- Metabolic DiseaseObesityCold Exposure
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 120
- Registration Number
- NCT06424132
- Locations
- đşđ¸
Rockefeller University, New York, New York, United States
Myokine Identification Following Acute Exercise
- Conditions
- Adiposity
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 12
- Registration Number
- NCT06223035
- Locations
- đşđ¸
Rockefeller University, New York, New York, United States
Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress
- Conditions
- Stress, PsychologicalRacism
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 22
- Registration Number
- NCT06146218
- Locations
- đşđ¸
Recrutment Office, New York, New York, United States
HepB MAb19 in Individuals with Chronic Hepatitis B Infection
- Conditions
- Hepatitis B VirusHepatitis B
- Interventions
- Other: Sterile Saline
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 37
- Registration Number
- NCT05856890
- Locations
- đşđ¸
NYU Langone Health, New York, New York, United States
đşđ¸The Rockefeller University, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 25
- Next
News
Engineered CD40 Antibody Achieves Complete Cancer Remission in Phase 1 Trial
A modified CD40 agonist antibody called 2141-V11 demonstrated remarkable efficacy in a phase 1 clinical trial, with six of 12 patients experiencing significant tumor reduction and two achieving complete remission.
Insights into Fibrolamellar Carcinoma Lead to New Clinical Trial
⢠Researchers have identified a unique transcriptomic signature for fibrolamellar hepatocellular carcinoma (FLC), distinguishing it from other liver cancers. ⢠A clinical trial has been initiated, combining DT2216 and irinotecan, showing promise in preliminary results against FLC. ⢠The study highlights the importance of examining tumor margins for hidden FLC cells to prevent potential recurrence. ⢠The research suggests defining cancer by its impact on protein activity balance rather than solely by DNA changes.
Novel Enzyme Shows Promise in Treating IgG-Mediated Autoimmune Diseases
Researchers at Emory University have identified a novel enzyme, CU43, that effectively reduces IgG-mediated pathologies in mouse models of autoimmune diseases.